Observational studyJapanese journal of ophthalmology2020
Time course of changes in contrast sensitivity following intravitreal ranibizumab injection for branch retinal vein occlusion.
Observational study in Japanese journal of ophthalmology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Non-inferiority study of the efficacy of ranibizumab BS compared with aflibercept in patients with macular oedema due to untreated branch retinal vein occlusion: REMEDY-BRVO study - study protocol.BMJ open ophthalmology · 2026Article
- Clinical and Molecular Characteristics of Foveal Sparing Phenotype in Chinese Patients With Inherited Retinal Diseases.Translational vision science & technology · 2026Article
- Association Between Contrast Sensitivity and Ganglion Cell-Inner Plexiform Layer Thickness After Resolution of Macular Edema Due to Branch Retinal Vein Occlusion.Journal of clinical medicine · 2025Article
- Visual Acuity and Retinal Thickness and Sensitivity after Intravitreal Ranibizumab Injection for Macular Edema in Branch Retinal Vein Occlusion.Journal of clinical medicine · 2024Article
- Time course of changes in vision-related quality of life following intravitreal ranibizumab treatment for branch retinal vein occlusion.Scientific reports · 2022Observational
- Relationship between stereopsis and vision-related quality of life in patients with branch retinal vein occlusion.BMJ open ophthalmology · 2022Observational
- Aniseikonia following intravitreal ranibizumab treatment for branch retinal vein occlusion.Japanese journal of ophthalmology · 2021Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate contrast sensitivity (CS) in patients with branch retinal vein occlusion (BRVO) following intravitreal ranibizumab injection (IVR), and to investigate the relationship between CS and retinal microstructure.
designA retrospective, observational case series.
methodsWe included 23 eyes with treatment naïve BRVO followed up for 6 months after treatment. Best-corrected visual acuity (BCVA), letter contrast sensitivity (LC), and 10% low contrast visual acuity (LCVA) were measured. All tests were performed before and 1, 2, 3, 4, 5, and 6 months after treatment. Based on optical coherence tomography (OCT) images, we assessed central retinal thickness (CRT), presence of serous retinal detachment (SRD), and status of the external limiting membrane (ELM) and ellipsoid zone (EZ).
resultsIVR treatment significantly improved CS (LC: P < 0.0001, LCVA: P = 0.004) as well as BCVA (P = 0.015) and CRT (P < 0.0001). LC and LCVA at 6 months after treatment were significantly correlated with presence of SRD before treatment. At 6 months after treatment, LCVA was significantly correlated with pre-treatment CRT (P = 0.042). In patients with good baseline BCVA, LCVA showed significant improvements (P = 0.022) although their BCVA did not change. In patients with poor improvement in BCVA, LC and LCVA also showed significant improvements (P = 0.008, P = 0.005).
conclusionIVR treatment for BRVO improves both BCVA and CS. Even in patients without any improvement in visual acuity, CS does improve.
Indexed as
Identifiers
32691257What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.